{"id":686,"date":"2025-02-17T08:17:21","date_gmt":"2025-02-16T23:17:21","guid":{"rendered":"http:\/\/www.tunascompany.com\/tunascompany.com\/?page_id=686"},"modified":"2025-03-28T08:32:05","modified_gmt":"2025-03-27T23:32:05","slug":"%e7%b5%84%e6%8f%9b%e3%81%88%e9%ba%bb%e7%96%b9%e3%82%a6%e3%82%a4%e3%83%ab%e3%82%b9%e3%82%92%e7%94%a8%e3%81%84%e3%81%9f%e8%85%ab%e7%98%8d%e6%ba%b6%e8%a7%a3%e6%80%a7%e3%82%a6%e3%82%a4%e3%83%ab%e3%82%b9","status":"publish","type":"page","link":"https:\/\/plaza.umin.ac.jp\/kailab\/%e7%b5%84%e6%8f%9b%e3%81%88%e9%ba%bb%e7%96%b9%e3%82%a6%e3%82%a4%e3%83%ab%e3%82%b9%e3%82%92%e7%94%a8%e3%81%84%e3%81%9f%e8%85%ab%e7%98%8d%e6%ba%b6%e8%a7%a3%e6%80%a7%e3%82%a6%e3%82%a4%e3%83%ab%e3%82%b9\/","title":{"rendered":"\u7d44\u63db\u3048\u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9\u3092\u7528\u3044\u305f\u816b\u760d\u6eb6\u89e3\u6027\u30a6\u30a4\u30eb\u30b9\u306e\u958b\u767a"},"content":{"rendered":"\n
<\/span>
<\/div>
\n
\n

\u30a6\u30a3\u30eb\u30b9\u3092\u7528\u3044\u305f\u304c\u3093\u6cbb\u7642<\/h2>\n<\/div>\n<\/div><\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n

\u3000\u3000\u79c1\u305f\u3061\u306f\u3001\u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9\uff08HL\u682a\uff09\u304c\u3001\u4e73\u304c\u3093\u3092\u306f\u3058\u3081\u3068\u3059\u308b\u69d8\u3005\u306a\u304c\u3093\u7d30\u80de\u306b\u5bfe\u3057\u3066\u5f37\u3044\u50b7\u5bb3\u6027\u3092\u6301\u3064\u3053\u3068\u3092\u898b\u51fa\u3057\u307e\u3057\u305f\u3002\u3055\u3089\u306b\u30ea\u30d0\u30fc\u30b9\u30b8\u30a7\u30cd\u30c6\u30a3\u30af\u30b9\u3092\u7528\u3044\u3066\u3053\u306e\u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9\u682a\u306b\u907a\u4f1d\u7684\u6539\u5909\u3092\u65bd\u3057\u3001\u306f\u3057\u304b\u3092\u5f15\u304d\u8d77\u3053\u3055\u305a\u306b\u304c\u3093\u7d30\u80de\u306b\u9078\u629e\u7684\u306b\u611f\u67d3\u3057\u3066\u816b\u760d\u6eb6\u89e3\u80fd\u3092\u767a\u63ee\u3059\u308b\u7d44\u63db\u3048\u30a6\u30a4\u30eb\u30b9\uff08rMV-SLAMblind\uff09\u3092\u4f5c\u51fa\u3057\u307e\u3057\u305f\u3002<\/p>\n\n\n\n

\u3000\u3053\u308c\u307e\u3067\u306e\u7814\u7a76\u306b\u3088\u308a\u3001rMV-SLAMblind\u306f\u3001\u4e73\u304c\u3093\u3001\u80ba\u304c\u3093\u3001\u5927\u8178\u304c\u3093\u3001\u81b5\u81d3\u304c\u3093\u3001\u3068\u3044\u3063\u305f\u69d8\u3005\u306a\u304c\u3093\u306b\u5bfe\u3057\u3066\u3001\u62c5\u304c\u3093\u30de\u30a6\u30b9\u30e2\u30c7\u30eb\u3067\u9855\u8457\u306a\u6297\u816b\u760d\u52b9\u679c\u3092\u767a\u63ee\u3059\u308b\u3053\u3068\u304c\u308f\u304b\u308a\u3001\u65b0\u305f\u306a\u304c\u3093\u6cbb\u7642\u6cd5\u3068\u3057\u3066\u6709\u671b\u3067\u3042\u308b\u3068\u671f\u5f85\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n\n\n\n


\u3000\u6211\u3005\u306e\u958b\u767a\u3057\u305f\u816b\u760d\u6eb6\u89e3\u6027\u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9\u306e\u81e8\u5e8a\u958b\u767a\u8a08\u753b\u306f\u65e5\u672c\u533b\u7642\u7814\u7a76\u958b\u767a\u6a5f\u69cb\uff08AMED\uff09\u306e\u300c\u9769\u65b0\u7684\u304c\u3093\u533b\u7642\u5b9f\u7528\u5316\u7814\u7a76\u4e8b\u696d\u300d<\/strong>\u306e\u652f\u63f4\u3092\u53d7\u3051\u3066\u6a4b\u6e21\u3057\u7814\u7a76\u3092\u9032\u3081\u3066\u304d\u307e\u3057\u305f\u3002\u73fe\u5728\u3001\u533b\u5e2b\u4e3b\u5c0e\u6cbb\u9a13\u3092\u5b9f\u65bd\u4e2d\u3067\u3059\u3002<\/p>\n\n\n\n

https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT2033210698<\/a><\/p>\n<\/div>\n\n\n\n

\n

\u539f\u8457\u8ad6\u6587<\/h3>\n\n\n\n
    \n
  1. Tamura K, Fujiyuki T, Moritoh K, Akimoto H, Iizuka K, Sato H, Asano K, Yoneda M, Kai C. (2023)
    Anti-tumor activity of a recombinant measles virus against canine lung cancer cells. <\/a>
    Scientific Reports<\/em><\/strong>, 13, 18168. DOI:10.1038\/s41598-023-42305-9<\/li>\n\n\n\n
  2. Moritoh K, Shoji K, Amagai Y, Fujiyuki T, Sato H, Yoneda M, Kai C. (2023) 
    Immune response elicited in the tumor microenvironment upon rMV-SLAMblind cancer virotherapy. <\/a>
    Cancer Science<\/em><\/strong>, 114, 2158-2168. DOI: 10.1111\/cas.15740<\/li>\n\n\n\n
  3. Fujiyuki T, Amagai Y, Shoji K, Kuraishi T, Sugai A, Awano M, Sato H, Hattori S, Yoneda M, Kai C. (2020)
    Recombinant SLAM-blind measles virus is a promising candidate for necctin-4-positive triple negative breast cancer therapy.<\/a> 
    Molecular Therapy-Oncolytics<\/em><\/strong>, 19, 127-135. DOI: 10.1016\/j.omto.2020.09.007<\/li>\n\n\n\n
  4. Iizuka K, Shoji K, Fujiyuki T, Moritoh K, Tamura K, Yoshida A, Sato H, Yoneda M, Asano K, Kai C. (2020)
    Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells. <\/a>
    Research in Veterinary Science<\/em><\/strong>, 133, 313-317. DOI: 10.1016\/j.rvsc.2020.10.016<\/li>\n\n\n\n
  5. Awano M, Fujiyuki T, Shoji K, Amagai Y, Murakami Y, Furukawa Y, Sato H, Yoneda M, Kai C. (2016)\u3000
    Measles virus selectively blind to SLAM has oncolytic efficacy against nectin-4-expressing pancreatic cancer cells. <\/a>
    Cancer Science<\/em><\/strong>, 107, 1647-52. DOI: 10.1111\/cas.13064<\/li>\n\n\n\n
  6. Amagai Y, Fujiyuki T, Yoneda M, Shoji K, Furukawa Y, Sato H, Kai C. <\/strong>(2016)
    Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells. <\/a>
    Scientific Reports<\/em><\/strong>, 6, 24572. DOI: 10.1038\/srep24572<\/li>\n\n\n\n
  7. Shoji K, Yoneda M, Fujiyuki T, Amagai Y, Tanaka A, Matsuda A, Ogihara K, Naya Y, Ikeda F, Matsuda H, Sato H, Kai C. (2016) 
    Development of new therapy for canine mammary cancer with recombinant measles virus. <\/a>
    Molecular Therapy-Oncolytics<\/em><\/strong>, 3, 15022. DOI:10.1038\/mto.2015.22<\/li>\n\n\n\n
  8. Fujiyuki T, Yoneda M, Amagai Y, Obayashi K, Ikeda F, Shoji K, Murakami Y, Sato H, Kai C. (2015) 
    A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells. <\/a>
    Oncotarget<\/em><\/strong>, 6, 24895-24903. DOI: 10.18632\/oncotarget.4366<\/li>\n\n\n\n
  9. Sugiyama T, Yoneda M, Kuraishi T, Hattori S, Inoue Y, Sato H, Kai C. (2013) 
    Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. <\/a>
    Gene Therapy<\/em><\/strong>, 20, 338-47. DOI: 10.1038\/gt.2012.44<\/li>\n<\/ol>\n\n\n\n

    \u548c\u6587\u7dcf\u8aac<\/h3>\n\n\n\n
      \n
    1. \u7532\u6590\u77e5\u60e0\u5b50\u3001\u85e4\u5e78\u77e5\u5b50\u3001\u7c73\u7530\u7f8e\u4f50\u5b50 (2024) 
      \u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9\u3092\u7528\u3044\u305f\u30a6\u30a4\u30eb\u30b9\u7642\u6cd5. 
      Precision Medicine<\/em><\/strong>, 7, 28-31.<\/li>\n\n\n\n
    2. \u7532\u6590\u77e5\u6075\u5b50\u3000(2016) 
      \u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9\u3092\u7528\u3044\u305f\u816b\u760d\u6eb6\u89e3\u6027\u30a6\u30a4\u30eb\u30b9\u7642\u6cd5\uff08\u7279\u96c6\uff1a\u65b0\u85ac\u8a8d\u53ef\u3067\u6cbb\u7642\u9769\u547d\u306e\u5e55\u958b\u3051\u3000\u304c\u3093\u306e\u30a6\u30a4\u30eb\u30b9\u7642\u6cd5\uff09 
      \u5b9f\u9a13\u533b\u5b66<\/em><\/strong>\u300134, 26-30.<\/li>\n<\/ol>\n\n\n\n

      \u8457\u66f8<\/h3>\n\n\n\n
        \n
      1. \u7532\u6590\u77e5\u60e0\u5b50\u3001\u85e4\u5e78\u77e5\u5b50\u3001\u7c73\u7530\u7f8e\u4f50\u5b50 (2023) 
        \u7b2c4\u7bc0\u304c\u3093in vivo<\/em>\u907a\u4f1d\u5b50\u6cbb\u7642\u30003.\u30a6\u30a4\u30eb\u30b9\u7642\u6cd5 7.\u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9. 
        \u4e00\u822c\u793e\u56e3\u6cd5\u4eba\u65e5\u672c\u907a\u4f1d\u5b50\u7d30\u80de\u6cbb\u7642\u5b66\u4f1a\u7de8\uff0f\u85e4\u5802\u5177\u7d00\u76e3\u4fee<\/em><\/strong>. \u907a\u4f1d\u5b50\u6cbb\u7642\u958b\u767a\u7814\u7a76\u30cf\u30f3\u30c9\u30d6\u30c3\u30af\u3000\u7b2c2\u7248. 435-439.<\/li>\n<\/ol>\n<\/div>\n\n\n\n
        \n

        \u7d44\u63db\u3048\u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9\u3092\u7528\u3044\u305f\u816b\u760d\u6eb6\u89e3\u6027\u30a6\u30a4\u30eb\u30b9\u306e\u958b\u767a<\/h2>\n\n\n\n
        \n
        \n

        \u3000\u5f53\u7814\u7a76\u5ba4\u306f\u9577\u3044\u7d4c\u9a13\u306e\u4e2d\u3067\u3001\u6211\u3005\u306e\u6301\u3064\u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9HL\u682a\u304c\u4e73\u304c\u3093\u3092\u306f\u3058\u3081\u3001\u69d8\u3005\u306a\u304c\u3093\u7d30\u80de\u306b\u5bfe\u3057\u3066\u5f37\u3044\u969c\u5bb3\u6027\u3092\u6301\u3064\u3053\u3068\u3092\u898b\u51fa\u3057\u307e\u3057\u305f\u3002\u3055\u3089\u306b\u30ea\u30d0\u30fc\u30b9\u30b8\u30a7\u30cd\u30c6\u30a3\u30af\u30b9\u3092\u7528\u3044\u3066\u3053\u306e\u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9\u682a\u306b\u907a\u4f1d\u7684\u6539\u5909\u3092\u65bd\u3057\u3001\u306f\u3057\u304b\u3092\u5f15\u304d\u8d77\u3053\u3055\u305a\u306b\u304c\u3093\u7d30\u80de\u306e\u307f\u306b\u9078\u629e\u7684\u306b\u611f\u67d3\u3057\u3066\u816b\u760d\u6eb6\u89e3\u80fd\u3092\u767a\u63ee\u3059\u308b\u7d44\u63db\u3048\u30a6\u30a4\u30eb\u30b9\uff08rMV-SLAMblind\uff09\u3092\u4f5c\u51fa\u3057\u307e\u3057\u305f\uff08\u4e0b\u56f3\uff09\u3002\u3053\u308c\u307e\u3067rMV-SLAMblind\u306f\u62c5\u764c\u30de\u30a6\u30b9\u30e2\u30c7\u30eb\u3067\u9855\u8457\u306a\u6297\u816b\u760d\u52b9\u679c\u3092\u767a\u63ee\u3059\u308b\u3053\u3068\u304c\u308f\u304b\u308a\u3001\u65b0\u305f\u306a\u304c\u3093\u6cbb\u7642\u6cd5\u3068\u3057\u3066\u6709\u671b\u3067\u3042\u308b\u3053\u3068\u304c\u793a\u5506\u3055\u308c\u3066\u3044\u307e\u3059\u3002
        \u3000\u73fe\u5728rMV-SLAMblind\u306e\u5b9f\u7528\u5316\u306b\u5411\u3051\u3066\u3001\u533b\u5e2b\u4e3b\u5c0e\u6cbb\u9a13\u3092\u76ee\u6307\u3057\u672c\u683c\u7684\u306b\u7814\u7a76\u958b\u767a\u306b\u53d6\u308a\u7d44\u3093\u3067\u3044\u307e\u3059\u3002<\/p>\n<\/div>\n\n\n\n

        \n
        \"\u7d44\u307f\u66ff\u3048\u9ebb\u75b9\u30a6\u30a4\u30eb\u30b9\u3092\u7528\u3044\u305f\u816b\u760d\u6eb6\u89e3\u6027\u30a6\u30a4\u30eb\u30b9\u306e\u958b\u767a\"\n\t\t\t\n\t\t\t\t\n\t\t\t<\/svg>\n\t\t<\/button>
        \n